Bering Partners Reports 9.99% Stake After Warrant Issuance
CALC sits 24% above its 52-week low of $0.461 on light trading volume (0.2× avg).
Summary
Bering Partners II and affiliates, including director Evgeny Zaytsev, report a 9.99% stake in CalciMedica after receiving Series A and Series B warrants upon stockholder approval.
Key Events · Ownership and Investor Activity · CALC
-
9.99% Stake Reported
Bering Partners II, L.P. and affiliated entities, including director Evgeny Zaytsev, report beneficial ownership of 3,553,398 shares, representing 9.99% of CalciMedica's outstanding common stock.
-
Warrant Issuance Completed
Stockholder approval for Series A and Series B warrants was obtained on August 19, 2026, and the warrants were issued the same day, adding 1,439,885 shares underlying warrants exercisable within 60 days to the reported stake.
-
Beneficial Ownership Limitation
An additional 1,591,300 shares underlying warrants (795,650 Series A and 795,650 Series B) are excluded from the reported total due to a 9.99% beneficial ownership limitation.
-
Prior Investment Context
This filing follows the initial Schedule 13D filed July 3, 2026, disclosing a $1.16 million investment in CalciMedica's private placement, and the subsequent appointment of Evgeny Zaytsev to the board on July 7, 2026.
Analysis · CALC · Life Sciences
Bering Partners II, L.P. and affiliated entities, including director Evgeny Zaytsev, now hold 3,553,398 shares of CalciMedica, representing 9.99% of the outstanding common stock. This follows stockholder approval on August 19, 2026, for the issuance of Series A and Series B warrants, which were issued the same day. The reported stake includes 2,113,513 common shares and 1,439,885 shares underlying warrants exercisable within 60 days. An additional 1,591,300 shares underlying warrants are excluded due to a 9.99% beneficial ownership limitation. This filing quantifies the full ownership position after the warrant issuance, providing clarity on the investor's influence and potential future dilution.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.7% of the 1731 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CALC was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.6M. The 52-week trading range was $0.46 to $7.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.